A randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis

Clinical Otolaryngology and Allied Sciences

Volumn 27, Issue 6, 2002, Pages 489-493

  Fowler, P D ^a   Gazis, A G ^a   Page, S R ^a   Jones, N S ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Betamethasone; Bone turnover; Fluticasone; Glucocorticoids; Nasal polyps; Pituitary adrenal system

Indexed keywords

BETAMETHASONE; BETAMETHASONE SODIUM PHOSPHATE; FLUTICASONE; FLUTICASONE PROPIONATE; TETRACOSACTIDE;

ADULT; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENCY; EYE IRRITATION; EYE PAIN; FEMALE; HEADACHE; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; LIVER METABOLISM; MALE; NOSE MUCOSA; NOSE POLYP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROAT DISEASE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADMINISTRATION, INTRANASAL; ADULT; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; BONE AND BONES; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; NASAL POLYPS; PITUITARY-ADRENAL SYSTEM;

EID: 0036936743     PISSN: 03077772     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2273.2002.00627.x     Document Type: Article

References (21)

1. Stevens D. (1988) Cushing's syndrome due to the abuse of betamethasone nasal drops. J. Laryngol. Otol. 102, 219-221
2. Nutting C. & Page S. (1995) Iatrogenic Cushing's syndrome due to nasal betamethasone: A problem not to be sniffed at! Postgrad. Med. J. 71, 231-232
3. Gazis A., Homer J., Henson D. et al. (1999) The effect of six weeks topical nasal betamethasone drops on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clin. Otorhinolaryngol. 24, 495-498
4. Anon (1998) The safety of inhaled and nasal corticosteroids. Curr. Problems Pharmacovigilance 24, 8
5. Tordjman K., Jaffe A., Trostanetsky Y. et al. (2000) Low dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: Sensitivity, specificity and accuracy in comparison with the high dose (250 microgram) test. Clin. Endocrinol. 52, 633-640
6. Thaler L. & Blevins L. (2001) The low dose (1 microgram) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J. Clin. Endocrinol. Metabolism 83, 2726-2729
7. Rosen H., Moses A., Garber J. et al. (2000) Serum CTx: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calif. Tissue Int. 66, 100-103
8. Tahtela R., Turpeinen M., Sorva R. et al. (1997) The aminoterminal propeptide of type 1 procollagen: Evaluation of a commercial radioimmunoassay kit and values in healthy subjects. Clin. Biochem. 30, 35-40
9. Piccirillo J., Edwards, D., Haiduk, A. et al. (1995) Psychometric and clinimetric validity of the 31-item rhinosinusitis outcome measure (RSOM-31). Am. J. Rhinol. 9, 297-306
10. Gill G., Swift A., Jones A. et al. (2001) Severe adrenal suppression by steroid nasal drops. J. R. Soc. Med. 94, 350-351
11. Findlay C., MacDonald J. & Wallace A. (1998) Childhood Cushing's syndrome induced by betamethasone nose drops, and repeat prescriptions. BMJ 317, 739-740
12. Lipworth B. & Seckl J. (1997) Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 52, 476-482
13. Wilson A., Macfarlane L. & Lipworth B. (1998) Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal axis activity. J. Allergy Clin. Immunol. 101, 470-474
14. Pearce G., Tabensky A., Delmas P. et al. (1997) Corticosteroid-induced bone loss in men. J. Clin. Endocrinol. Metabolism 83, 801-806
15. Ebeling P., Erbas P., Hopper J. et al. (1998) Bone mineral density and bone turnover in asthmatics treated with long term inhaled or oral glucocorticoids. J. Bone Mineral Res. 13, 1283-1289
16. Geddes D. (1992) Inhaled corticosteroids: Benefits and risks. Thorax 47, 404-407
17. Egan J., Maden C., Kalra S. et al. (1999) A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. Eur. Resp. J. 13, 1267-1275
18. Tattersfield A., Town G., Johnell O. et al. (2001) Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax 56, 272-278
19. Charlton R., Mackay I., Wilson R. et al. (1985) Double blind placebo controlled trial of betamethasone nasal drops for nasal polyposis. BMJ 291, 788
20. Keith P., Nieminen J., Hollingworth K. et al. (2000) Efficacy and tolerability of fluticasone propionate nasal drops 400 micrograms once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin. Exp. Allergy 30, 1460-1468
21. Allen D.B. (2000) Systemic effects of intranasal steroids: An endocrinologist's perspective. J. Allergy Clin. Immunol. 106 (Suppl. 4), S179-90